Cynthia Cernak
Podiatrist · Mount Pleasant, WINPI 1467493197
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 98 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $343 and has fallen 94.2% since, to $20 in 2025.
Across 98 payments — averaging $14.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$264
- AbbVie$204
- Novo Nordisk$182
- IBSA Pharma Inc.$119
- Lilly USA, LLC$92
- Smith+Nephew$67
- plus $474 from 19 others
What the payments were for
- Food & beverage$1,403100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 39 | $264 |
| AbbVie | 9 | $204 |
| Novo Nordisk | 10 | $182 |
| IBSA Pharma Inc. | 7 | $119 |
| Lilly USA, LLC | 5 | $92 |
| Smith+Nephew | 4 | $67 |
| Nestle Healthcare Nutrition Inc. | 3 | $55 |
| Next Science LLC | 2 | $52 |
| Integra Lifesciences Corporation | 1 | $50 |
| Organogenesis Inc. | 2 | $36 |
| ANI Pharmaceuticals, Inc. | 1 | $29 |
| Melinta Therapeutics, LLC | 2 | $28 |
| Orthofix Medical, Inc. | 1 | $26 |
| Exact Sciences | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Celularity Inc. | 1 | $16 |
| Pfizer | 1 | $16 |
| Merck | 1 | $16 |
| Zimmer Biomet | 1 | $15 |
| Osiris Therapeutics Inc. | 1 | $15 |
| Stryker | 1 | $15 |
| Nevro Corp. | 1 | $14 |
| Tactile Systems Technology Inc | 1 | $11 |
How this compares
$1,403 in reported general payments places this provider in the 60th percentile of 140 podiatrist providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Terbinafine Hcl | 11 | $266 |
| Gentamicin Sulfate | 23 | $241 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Mount Pleasant
- Anne StrozeMount Pleasant$4K
- Bradley Abichtla Crosse$308K
- Scott Carringtonla Crosse$116K
- Jason DevriesManitowoc$31K
- Randall DeiFranklin$20K
- Jacob HagenbucherMadison$13K
- Andrea CifaldiEau Claire$13K
- Jonathan ShihFranklin$11K
- Naren PatelMadison$10K
- Brandon ScharerGreen Bay$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.